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ACE–PrEvEntion PAmPhlEts sEriEs  
ovErAll rEsults PAmPhlEt 2 
CombinEd rEsults for Dominant And Very 
Cost-EffECtivE PrEvEntion intErvEntions
1. Main Messages
•	 There	is	a	great	opportunity	for	considerable	health	gain	from	a	package	of	43	very	cost-effective	
prevention	options	(listed	in	Table	1).
•	 Addressing	the	inefficiency	of	current	preventive	drug	treatment	for	cardiovascular	disease	(by	choosing	
the	most	cost-effective	drugs	and	targeting	those	at	absolute	risk	rather	than	individual	risk	factor	
thresholds)	could	free	up	enough	resources	in	the	short	term	to	fund	most	of	the	43	recommended	
interventions.
•	 Large	cost	savings	in	the	medium	to	longer	term	can	be	expected	by	reducing	the	need	to	treat	disease.
•	 Implementation	of	the	recommended	package	calls	for	political	will,	particularly	for	the	taxation	and	
regulation	interventions.	This	study	provides	compelling	evidence	to	make	these	changes.
•	 A	large	number	of	the	recommended	interventions	are	delivered	by	primary	care	services	and	may	require	
a	combination	of	training	and	incentives	to	facilitate	general	practitioners	to	comply.
•	 The	recommended	preventive	drug	interventions	would	require	a	large	number	of	people	to	take	
medication	for	the	rest	of	their	lives.	Introduction	of	a	polypill	for	cardiovascular	disease	prevention	could	
enhance	the	adherence	to	multiple	preventive	drug	treatment.
2. Background
The	ACE-Prevention	project	evaluated	the	cost-effectiveness	of	123	preventive	health	interventions,	with	a	
near	comprehensive	focus	on	lifestyle	risk	factors	and	non-communicable	chronic	diseases.	The	risk	factor	
and	disease	interventions	have	been	modelled	independently,	but	many	have	common	disease	outcomes.	To	
determine	the	combined	effect	of	the	most	cost-effective	preventive	interventions	on	the	total	costs	and	health	
outcomes,	the	43	most	cost-effective	interventions	(Table	1)	have	been	re-evaluated	in	a	large	combined	model	
that	integrates	all	relevant	risk	factors	and	disease	parameters.	This	combined	modelling	takes	into	account	the	
shared	intervention	costs	(e.g.	for	general	practitioner	visits)	and	shared	outcomes	(e.g.	the	effects	of	blood-
pressure	lowering	drugs,	tobacco	tax	and	mandatory	salt	limits	in	processed	food	on	stroke	and	heart	disease).
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3. interVentions
We	have	evaluated	the	total	intervention	costs,	cost	offsets	and	health	gain	associated	with	implementing	the	package	of	interventions	
that	are	Dominant	(i.e.	cost-saving)	and	the	package	of	interventions	that	are	Dominant	or	Very Cost-Effective	(i.e.	all	interventions	with	
cost-effectiveness	less	than	$10,000	per	DALY).	For	comparison,	we	also	simulated	current	practice,	which	largely	reflects	the	current	use	
and	prescribing	practices	for	the	blood	pressure	and	cholesterol	lowering	drugs	used	for	preventing	cardiovascular	disease.
4. cHoice of coMparator
The	packages	of	interventions	were	evaluated	in	the	combined	model	in	comparison	to	a	partial	null	(‘no	intervention’)	scenario,	a	
hypothetical	back-calculation	that	takes	away	the	impact	of	current	practice.	
5. interVention cost-effectiVeness
Results	are	presented	over	time	from	the	baseline	year	of	2003	to	illustrate	the	timing	of	investment	in	intervention	packages	(the	red	
bars	in	Figure	1)	and	return	in	the	form	of	population	health	improvements	(the	green	line	in	Figure	1)	and	disease	and	injury	cost	offsets	
(the	blue	bars	in	Figure	1).	Note	that	the	estimates	of	costs	and	outcomes	over	time	pertain	only	to	the	2003	Australian	population	
as	they	age	and	eventually	die.	The	modelling	does	not	include	younger	people	from	2003	onwards	who	become	eligible	for	the	
interventions.
doMinant interVention package
The	package	of	23	Dominant	interventions	(Table	1)	could	avert	1	million	DALYs	over	the	lifetime	of	the	2003	Australian	population	(as	
represented	by	the	area	under	the	green	curve	in	Figure	1).	Eighty	percent	of	this	health	gain	could	be	achieved	with	the	taxation	and	
regulation	interventions	on	salt,	alcohol	and	tobacco,	and	the	polypill	(cheap	generic	blood	pressure	and	cholesterol	lowering	drugs	in	a	
single	pill)	for	cardiovascular	disease	prevention.
The	package	of	Dominant	interventions	would	cost	$4.6	billion	(the	sum	of	each	of	the	red	bars	in	Figure	1),	but	could	avert	$11	billion	in	
health	care	costs	(the	sum	of	the	blue	bars	in	Figure	1).	Fourteen	percent	of	the	investment	would	be	required	in	the	first	year,	with	lower	
annual	costs	thereafter	for	the	on-going	delivery	of	drugs	for	cardiovascular	disease	prevention	(Figure	1).	The	health	care	costs	saved	
would	reach	a	peak	around	12	years	after	intervention.	The	extension	of	life	from	implementing	this	set	of	interventions	would	lead	to	a	
small	net	additional	disease	treatment	cost	from	2059	only.	
Figure	2	shows	an	overlay	of	costs	(the	purple	bars	in	Figure	2),	health	impact	(the	orange	curve	in	Figure	2)	and	disease	treatment	costs	
saved	(	the	light	blue	bars	in	Figure	2)	by	current	practice	in	prevention	on	the	previous	graph.	The	costs	of	implementing	the	Dominant	
package	of	interventions	are	substantially	less	than	is	currently	spent	on	blood	pressure	and	cholesterol	lowering	drugs	and	lifestyle	
management	for	preventing	cardiovascular	disease.	Current	assessment	and	management	practices	are	more	costly	and	lead	to	less	
health	gain	and	less	treatment	costs	averted	than	could	be	achieved	with	the	Dominant	intervention	package.	In	part,	this	is	because	
of	the	inefficiency	of	current	practice	in	blood	pressure	and	cholesterol	lowering	due	to	a	preference	for	expensive	drugs	and	the	
inadequate	targeting	of	people	at	risk	based	on	individual	risk	factor	levels	rather	than	absolute	cardiovascular	risk.	Also,	the	taxation	
and	regulation	interventions	in	the	Dominant	intervention	package	reduce	the	need	for	preventive	cardiovascular	disease	drugs	which	
remain	expensive	even	if	prescribed	most	efficiently.
Figure	1:	Intervention	costs,	cost	offsets	and	health	gain	with	the	package	of	Dominant	(cost-saving)	preventive	interventions.
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Very cost-effectiVe interVention package
Adding	Very	Cost-Effective	interventions	with	cost-effectiveness	between	zero	and	$10,000/DALY	(Table	1)	to	the	package	of	
Dominant	interventions	leads	to	substantially	greater	up-front	costs	of	intervention	(the	orange	bars	in	Figure	3a).	Total	cost	
of	the	package	of	Dominant	and	Very Cost-Effective	interventions	would	be	$13	billion	(the	sum	of	the	orange	bars),	but	this	
would	be	more	than	matched	over	time	by	$14	billion	in	reduced	costs	of	health	care	(the	sum	of	the	light	blue	bars).	
A	total	of	1.4	million	DALYs	would	be	averted	by	the	package	of	Dominant	and	Very Cost-Effective	interventions,	which	is	
400,000	DALYs	more	than	the	Dominant	package	alone	(the	difference	between	the	purple	and	green	curves	in	Figure	
3a).	A	large	proportion	of	the	additional	health	gain	is	attributable	to	the	Polypill	interventions,	which	include	delivery	to	people	at	
more	than	5%	absolute	risk	or	at	least	55	years	in	age,	or	the	individual	cardiovascular	disease	drugs	if	the	polypill	is	not	implemented	
(compare	graphs	(a)	and	(b)	in	Figure	3).
6. conclusions
There	is	a	great	opportunity	for	considerable	health	gain	from	a	package	of	43	very	cost-effective	prevention	options.	Addressing	the	
inefficiency	of	current	preventive	drug	treatment	for	cardiovascular	disease	(by	choosing	the	most	cost-effective	drugs	and	targeting	
those	at	absolute	risk	rather	than	individual	risk	factor	thresholds)	could	free	up	enough	resources	in	the	short	term	to	fund	most	of	the	
43	recommended	interventions.	It	may	not	be	easy	to	redirect	these	resources	as	the	savings	to	the	Pharmaceutical	Benefits	Scheme	are	
not	easily	identified	as	funds	that	can	be	redirected	to	other	prevention	efforts.
Large	cost	savings	in	the	medium	to	longer	term	can	also	be	expected	by	reducing	the	need	to	treat	disease.	Also	here,	it	may	not	be	so	
easy	to	redirect	the	saved	treatment	costs	from	hospitals	into	prevention.	Therefore,	while	there	are	compelling	economic	arguments	
to	implement	this	prevention	package,	implementation	calls	for	political	will.	This	is	particularly	the	case	for	the	taxation	and	regulation	
interventions.	
A	large	number	of	the	recommended	interventions	are	delivered	by	primary	care	services	and	may	require	a	combination	of	training	and	
incentives	to	facilitate	general	practitioners	to	comply.	We	have	not	costed	such	measures	as	separate	interventions	but	instead	have	
made	‘realistic’	uptake	and	adherence	assumption	as	we	would	expect	under	routine	health	care	circumstances.
The	recommended	preventive	drug	interventions	would	require	a	large	number	of	people	to	take	medication	for	the	rest	of	their	lives	
and	this	may	meet	resistance	or	lead	to	poor	adherence.	Introduction	of	a	polypill	for	cardiovascular	disease	prevention	could	enhance	
the	adherence	to	multiple	preventive	drug	treatment.
Figure	3:	Intervention	costs,	cost	offsets	and	health	gain	with	the	package	of	Dominant	and	Very	Cost-Effective	(0	to	$10,000/DALY)	
preventive	interventions:	(a)	including	the	Polypill;	(b)	including	individual	blood	pressure	and	cholesterol	lowering	drugs	instead	of	the	
Polypill.
(a)		
(b)	
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Figure 3: Intervention costs, cost offsets and health gain with the package of Dominant and Very 
Cost-Effective (0 to $10,000/DALY) preventive interventions: (a) including the Polypill; (b) including 
individual blood pressure and cholesterol lowering drugs instead of the Polypill. 
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Table	1:	Dominant	and	Very	Cost-Effective	interventions
ACE,	angiotensin-converting	enzyme;	CCB,	calcium	channel	blocker;	CVD,	cardiovascular	disease
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Table 1: Dominant and Very Cost-Effective interventions 
Topic area Dominant interventions Very Cost-Effective interventions 
Alcohol • Volumetric tax 
• Tax increase 30% 
• Advertising bans 
• Raise minimum legal drinking age to 21 
• Brief alcohol intervention GP with or without 
telemarketing and support 
• Licensing controls 
Tobacco • Tax increase 30% (with or without 
indexation) 
• Cessation aids: varenicline, bupropion and 
nicotine replacement therapy 
Physical activity • Pedometers 
• Mass media 
• GP Green Prescription  
• Internet intervention 
Nutrition • Community fruit and vegetable intake 
promotion 
• Voluntary salt limits 
• Mandatory salt limits 
• Information mail-out, multiple re-tailored to 
promote fruit and vegetable intake 
Body mass • 10% tax on unhealthy food • Gastric banding for severe obesity 
Blood pressure 
and cholesterol 
• Community heart health program 
• Polypill $200 for >5% CVD risk 
• Low-dose diuretics >5% CVD risk 
• CCBs >10% CVD risk 
• ACE inhibitors >15% CVD risk  
• Polypill $200 to ages 55+ 
Mental disorders • Problem-solving post-suicide attempt 
• Treatment for individuals at ultra-high risk 
for psychosis 
• Screen and bibliotherapy to prevent adult and 
childhood depression  
• Screen and psychologist to prevent 
childhood/adolescent depression 
• Responsible media reporting for the reduction 
of suicide 
• Parenting intervention for the prevention of 
childhood anxiety disorders 
Osteoporosis  • Screen women aged 70+ and alendronate  
Hepatitis B • Vaccine and immunoglobulin to infants 
born to carrier or high-risk mothers 
• Universal infant vaccination 
 • High-risk infant vaccination  
 • Selective vaccination of infants with 
mothers from highly endemic countries 
 
Kidney disease • Proteinuria screen and ACE inhibitors for 
diabetics 
 
Oral health • Fluoridation drinking water, non-remote   
ACE, angiotensin-converting enzyme; CCB, calcium channel blocker; CVD, cardiovascular disease 
 
ACE–PrEvEntion PAmPhlEts
6. aBout ace-preVention
To aid priority setting in prevention, the Assessing Cost-Effectiveness in Prevention Project (ACE-Prevention) applies 
standardised evaluation methods to assess the cost-effectiveness of 100 to 150 preventive interventions, taking a health 
sector perspective. This information is intended to help decision-makers move resources from less efficient current 
practices to more efficient preventive action resulting in greater health gain for the same outlay.
Indigenous population results 
1.   Cardiovascular disease prevention 
2.   Diabetes prevention 
3.   Screening and early treatment of chronic kidney disease
Overall results 
1.   League table 
2.   Combined effects 
paMpHlets in tHis series 
Methods: 
A.   The ACE-Prevention project 
B.   ACE approach to priority setting 
C.   Key assumptions underlying the economic analysis 
D.   Interpretation of ACE-Prevention cost-effectiveness results 
E.   Indigenous Health Service Delivery 
General population results
1.		 Adult	depression
2.		 Alcohol
3.		 Blood	pressure	and	cholesterol	lowering
4.		 Cannabis
5.		 Cervical	cancer	screening,	Sunsmart	and	PSA	screening
6.		 Childhood	mental	disorders
7.		 Fruit	and	vegetables
8.	 HIV
9.	 Obesity
10.	 Osteoporosis
11.	 Physical	activity
12.	 Pre	diabetes	screening
13.	 Psychosis
14. Renal replacement therapy, screening and early treatment of chronic kidney disease
15. Salt
16. Suicide prevention
17. Tobacco 
